Guggenheim Maintains Buy on Damora Therapeutics, Lowers Price Target to $59
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains Damora Therapeutics (NASDAQ:DMRA) with a Buy and lowers the price target from $60 to $59.
Guggenheim analyst Michael Schmidt maintains Damora Therapeutics (NASDAQ:DMRA) with a Buy and lowers the price target from $60 to $59.